logo

For the Inventor, By the Inventor

Herzliya, Israel

Dekel Gelbman

This inventor holds 13 USPTO granted patents, plus 1 CIPO patent. Top assignee: Fdna, Inc.. Active years: 2016-2020.

USPTO Granted Patents = 13

% Patents Active = 100.0


Average Co-Inventor Count = 2.0

ph-index = 2

Forward Citations = 11(Granted Patents)


Location History:

  • Herzlia Pituach, IL (2016 - 2019)
  • Newton, MA (US) (2019 - 2020)

Company Filing History:

goldMedal13 out of 13 
 
Fdna, Inc.
 patents

Years Active: 2016-2020

Loading Chart...
Loading Chart...
13 patents (USPTO):Explore Patents
1. 10722181 - Systems, methods, and computer-readable media for using descriptors to identify when a subject is likely to have a dysmorphic feature (2020-07-28),
2. 10667689 - Systems, methods, and computer-readable media for patient image analysis to identify new diseases (2020-06-02),
3. 10470659 - Systems, methods, and computer-readable media for gene and genetic variant prioritization (2019-11-12),
4. 10327637 - Systems, methods, and computer-readable media for patient image analysis to identify new diseases (2019-06-25),
5. 10165983 - Systems, methods, and computer-readable media for determining a likely presence of a genetic disorder (2019-01-01),
6. 10016167 - Systems, methods, and computer-readable media for time lapse image comparison in genetic disorder analysis (2018-07-10),
7. 10004463 - Systems, methods, and computer readable media for using descriptors to identify when a subject is likely to have a dysmorphic feature (2018-06-26),
8. 9848829 - Systems, methods, and computer readable media for using descriptors to identify when a subject is likely to have a dysmorphic feature (2017-12-26),
9. 9668702 - Systems, methods, and computer readable media for using descriptors to identify when a subject is likely to have a dysmorphic feature (2017-06-06),
10. 9597037 - Systems, methods, and computer-readable media for determining when a subject is likely to be affected by a genetic disorder (2017-03-21),
11. 9579068 - Systems, methods, and computer readable media for using descriptors to identify when a subject is likely to have a dysmorphic feature (2017-02-28),
12. 9504428 - Systems, methods, and computer readable media for using descriptors to identify when a subject is likely to have a dysmorphic feature (2016-11-29),
13. 9392977 - Systems, methods, and computer readable media for using descriptors to identify when a subject is likely to have a dysmorphic feature (2016-07-19),

Title: The Innovative Mind of Dekel Gelbman

Introduction

Dekel Gelbman is a prominent inventor based in Herzlia Pituach, Israel. He has made significant contributions to the field of medical technology, holding a total of 13 patents. His work focuses on utilizing advanced systems and methods to improve patient diagnosis and treatment.

Latest Patents

Gelbman's latest patents include groundbreaking systems, methods, and computer-readable media designed to identify when a subject is likely to have a dysmorphic feature. These innovations involve processors that evaluate external soft tissue images and predict the likelihood of a subject being affected by a medical condition. Another notable patent addresses patient image analysis to identify new diseases. This system processes image data in conjunction with geographically dispersed genetic information to determine the likelihood of specific genetic variants, enhancing the understanding of genetic conditions.

Career Highlights

Throughout his career, Gelbman has demonstrated a commitment to advancing medical technology. His work at Fdna, Inc. has positioned him as a leader in the field, where he collaborates with other experts to push the boundaries of innovation in patient care.

Collaborations

Gelbman works closely with Yaron Gurovich, contributing to the development of cutting-edge technologies that aim to revolutionize medical diagnostics.

Conclusion

Dekel Gelbman's contributions to medical technology through his patents and collaborative efforts highlight his role as an influential inventor. His work continues to pave the way for advancements in patient diagnosis and treatment.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…